Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Clin Pract. 2007 May;61(5):826-34. Epub 2007 Mar 28.

The genetics of aspirin resistance.

Author information

1
Department of Clinical Pharmacology, Cardiovascular Division, King's College London, and Department of Clinical Neuroscience, Hammersmith Hospitals, London, UK. timothy.goodman@kcl.ac.uk

Abstract

Aspirin is widely used for the prophylaxis of cardiovascular events in patients with cardiovascular risk factors or established atherosclerotic disease. However, despite aspirin treatment, a substantial number of patients experience recurrent events. Such 'aspirin resistance' is generally defined as failure of aspirin to produce an expected biological response, for example inhibition of platelet aggregation or of thromboxane A2 synthesis. Whilst its aetiology is multifactorial, genetic factors are also likely to play their part. Here we review the evidence for and against such a genetic contribution, as well as the data suggesting the involvement of specific genes.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center